NCT00773474 - Lonafarnib in Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Lonafarnib

All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.

Trial Locations (6)

44106

Ireland Cancer Center - University Hospitals of Cleveland, Cleveland

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

47403

Cancer Care Center of Southern Indiana, Bloomington

47904

Arnett Cancer Care, Lafayette

47905

Horizon Oncology Center, Lafayette

61401

Medical & Surgical Specialists, LLC, Galesburg